Health & Research Goals
5-Amino-1MQ
5-Amino-1MQ (5-Amino-1-Methylquinolinium)
Primary Description
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that works by blocking the enzyme responsible for diverting nicotinamide away from NAD+ synthesis. By preserving the cellular nicotinamide pool, it elevates intracellular NAD+ levels, activates SIRT1 longevity pathways, and shifts adipocyte behavior from lipid storage toward lipid oxidation. While technically not a peptide by structure, it is widely distributed through peptide research vendors and is firmly embedded in the biohacker metabolic optimization community.
Key Benefits
- Fat cell reduction
- Metabolic enhancement
- Muscle preservation
Stable at room temperature in capsule form. No refrigeration required. High oral bioavailability demonstrated in Caco-2 assays with no significant efflux. Half-life estimated at approximately 6.9–16 hours in rodent models.
Demonstrated Effects
- Elevates intracellular NAD+ levels by blocking NNMT-mediated nicotinamide methylation
- Promotes lipolysis and fat oxidation in adipose tissue
- Supports lean mass preservation and body recomposition
- Activates SIRT1 pathways associated with longevity and insulin sensitivity
- Improves cellular energy metabolism and mitochondrial efficiency
- Reported reductions in visceral and subcutaneous fat in preclinical models
- Enhanced muscle strength and endurance performance — superior to exercise alone in aged animal models
- Increases S-adenosylmethionine (SAM) availability for epigenetic methylation
Proposed Mechanisms of Action
1. NNMT Inhibition
5-Amino-1MQ selectively blocks nicotinamide N-methyltransferase (NNMT) with an IC50 of approximately 1 µM. NNMT normally converts nicotinamide to 1-methylnicotinamide (1-MNA) — a metabolic dead end that depletes the nicotinamide pool. Blocking this enzyme preserves nicotinamide for NAD+ biosynthesis via the NAMPT salvage pathway.
Directly increases intracellular NAD+ in adipocytes and other metabolically active cells; reduces 1-MNA production.
2. NAD+ Elevation and SIRT1 Activation
By preserving nicotinamide, 5-Amino-1MQ increases NAD+ availability, which activates SIRT1 — a NAD+-dependent deacetylase ('longevity gene'). SIRT1 regulates insulin sensitivity, mitochondrial biogenesis, and fat oxidation gene expression.
Drives improved metabolic flexibility, insulin sensitivity, and lipolysis in fat tissue.
3. SAM Preservation and Epigenetic Remodeling
NNMT consumes S-adenosylmethionine (SAM) as the methyl donor in its reaction. Blocking NNMT preserves SAM, increasing its availability for histone methylation — particularly H3K4. This shifts gene expression in adipocytes toward a more metabolically active, less lipid-storing profile.
Epigenetic shift in fat cells away from lipid storage toward fat-burning phenotype.
4. Lipolysis Enhancement and Lipogenesis Inhibition
Downstream of SIRT1 activation and epigenetic remodeling, adipocyte gene expression favors lipid catabolism over anabolism — increasing the rate of fat breakdown while reducing formation of new fat deposits.
Measurable reductions in fat mass, particularly visceral adipose tissue, without muscle catabolism.
Research Evidence & Clinical Data
Investigated Applications
Fat Loss and Body Recomposition
Anecdotal: HighThe primary reason most biohackers use 5-Amino-1MQ. Community members report noticeable reductions in waist circumference and body fat percentage — typically within 4–8 weeks of consistent use — without significant loss of lean mass. Results are described as modest but reliable when paired with caloric control and exercise.
Preclinical basis: 29.3% fat mass reduction observed in obese mice versus diet alone; NNMT inhibition shifts adipocyte gene expression toward lipid catabolism.
NAD+ Optimization and Longevity
Anecdotal: ModerateBiohackers focused on healthspan and aging report using 5-Amino-1MQ as a complement to NAD+ precursor protocols, reasoning that blocking NNMT-mediated nicotinamide drain amplifies the effect of NMN and NR supplementation. Users describe improved energy levels, mental clarity, and subjective sense of cellular vitality.
Preclinical basis: NNMT inhibition increases intracellular NAD+, activates SIRT1, and shifts histone methylation patterns toward a metabolically younger profile.
Muscle Strength and Exercise Performance
Anecdotal: ModerateA growing subset of community users report improved endurance and reduced recovery time between sessions. Preclinical findings in aged mice showed enhanced grip strength and reduced performance decline with sustained training — which has attracted interest from older athletes and those focused on age-related muscle preservation.
Preclinical basis: 2024 mouse study: 5-Amino-1MQ improved grip strength beyond exercise alone and reduced performance tapering during sustained training, suggesting enhanced recovery capacity.
Insulin Sensitivity and Metabolic Health
Anecdotal: EmergingSome community members with metabolic syndrome or pre-diabetes report improved fasting glucose and reduced insulin resistance during cycles. SIRT1 activation by elevated NAD+ is the proposed mechanism, with downstream effects on glucose utilization and lipid handling.
Preclinical basis: SIRT1 activation via NAD+ elevation promotes insulin receptor sensitivity and improves glucose handling in adipose and muscle tissue.
Scientific References
- 1.
- 2.Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 DiabetesBiomed Res Int2021
Safety Profile
Common Side Effects
- Mild headache, particularly during initial dosing period
- Nausea or GI discomfort (usually transient)
- Jitteriness or elevated sense of alertness
- Insomnia if taken too late in the day
- Possible elevation in blood pressure (rare)
- Changes in appetite or thirst
- Unknown long-term safety profile — no completed human clinical trials
- Minimal reported
Contraindications
- Uncontrolled hypertension — potential sympathomimetic-like effects reported anecdotally
- Hyperthyroidism or active thyroid disorders
- Active cardiac arrhythmia or significant cardiovascular disease
- Pregnancy or breastfeeding — no safety data available
- Concurrent use of MAO inhibitors
- Known hypersensitivity to quinolinium compounds
- Pregnancy
- Liver disease
Pre-Use Screening Checklist
Anecdotal reports of elevated blood pressure and heart rate. Baseline BP and resting heart rate recommended before starting.
Useful to establish baseline for monitoring metabolic improvements and detecting any adverse shifts.
Metabolic acceleration from NNMT inhibition may compound hyperthyroid conditions.
WADA S0 prohibited substance — banned at all times for athletes subject to anti-doping regulations.
Legal & Regulatory Status
Not approved for any human use. No IND filed. Research chemical status — legal for laboratory research only in the United States.
Prohibited — classified under S0 (Non-Approved Substances). Banned at all times for athletes subject to WADA regulations.
No specific COFEPRIS ruling identified. Available through research peptide vendors. Not approved as a pharmaceutical.
Not approved. Research chemical status; regulations vary by member state.
Not TGA-approved. Classified as a Schedule 4 (prescription-only) or research chemical depending on formulation and context.
Research Protocols
Dosing Protocols
Standard fat loss and metabolic support
Oral (capsule)Conservative starting protocol
Oral (capsule)NAD+ longevity stack
OralRoutes of Administration
Oral (capsule)
Most common5-Amino-1MQ is available as pre-made oral capsules (typically 50 mg each). High passive membrane permeability confirmed in Caco-2 assays makes oral dosing effective.
No reconstitution needed. Store at room temperature away from light and moisture. Does not require refrigeration.
Subcutaneous injection
Less commonSome vendors offer injectable formulations. Sub-Q dosing starts at 2.5 mg once or twice daily. The injectable route may offer more consistent bioavailability but is far less popular in the community given the convenience of oral capsules.
If using injectable form: standard sub-Q injection technique into the abdominal fat fold. Requires bacteriostatic water reconstitution and sterile technique.
Reconstitution Guide
Not required for oral capsule form. For injectable lyophilized powder: bacteriostatic water.
For oral use: no reconstitution required. For injectable: add bacteriostatic water to lyophilized powder per vendor instructions.
Oral: typically pre-dosed at 50 mg per capsule. Injectable: vendor-specific — typically 5 mg/mL solutions.
Reconstituted injectable solution: refrigerate at 2–8°C, use within 30 days.
Oral capsules: room temperature, away from heat, light, and moisture. Lyophilized injectable: 2–8°C.
Morning dosing is preferred to align with natural metabolic activity. If split-dosing, take the second dose no later than early afternoon to avoid potential sleep disruption.
Pharmacokinetics
| Half-Life | Approximately 6.9 hours in rat plasma (LC-MS/MS pharmacokinetic study); some community sources cite 12–16 hours. Human data not established. |
| Absorption | High oral bioavailability confirmed in Caco-2 assay — high passive and active membrane transport with no significant efflux. Oral capsule form is practical and effective. |
| Distribution | Cell-permeable; enters adipocytes and other metabolically active cells. Distributes to adipose tissue, liver, and skeletal muscle based on preclinical data. |
| Metabolism | Hepatic metabolism presumed; specific CYP isoform data not established in published literature. |
| Molecular Structure | Quinolinium salt; MW approximately 159 Da (as free base). Cationic structure at physiological pH facilitates membrane penetration and intracellular access to NNMT. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Body composition and weightTrack fat mass vs. lean mass changes; ensure fat loss without muscle catabolism.Check: Weekly
- Fasting glucose and metabolic panelMonitor for positive shifts in fasting glucose, HbA1c, and lipid panel during cycles.Check: Every 4–8 weeks
- Blood pressure and heart rateAny significant elevation in resting BP or heart rate beyond baseline warrants dose reduction or discontinuation.Check: Weekly during first cycle
Critical Warning Signs
- Significant or sustained elevation in blood pressure (>20 mmHg above baseline)Discontinue use. Consult a healthcare provider. Do not resume without medical clearance.Urgency: Within 24-48 hours
- Chest pain, palpitations, or shortness of breathStop immediately and seek emergency medical attention.Urgency: IMMEDIATE
- Persistent insomnia or significant anxiety beyond the first weekReduce dose to 50 mg or switch to morning-only dosing. If unresolved, discontinue.Urgency: Within 1 week if persistent
Featured in Stacking Protocols
Community-researched combinations involving this compound
NMN (Nicotinamide Mononucleotide)
NAD+ Amplifier StackDual-pathway NAD+ optimization — precursor supply + drain prevention
NMN directly supplies NAD+ precursors via the salvage pathway. 5-Amino-1MQ prevents NNMT from diverting nicotinamide away from that same pathway. Together they address both sides of the NAD+ equation simultaneously.
5-Amino-1MQ 100 mg + NMN 250–500 mg, both taken orally in the morning.
AOD-9604
Fat Loss Synergy StackDual-mechanism fat loss — NNMT inhibition + direct lipolysis stimulation
5-Amino-1MQ shifts adipocyte gene expression toward fat burning; AOD-9604 directly activates beta-3 adrenergic receptors and promotes lipolysis. Complementary mechanisms targeting fat loss from different angles.
5-Amino-1MQ 100 mg oral daily + AOD-9604 300 mcg sub-Q in the morning fasted.
Semaglutide / GLP-1 agonists
Semaglutide / GLP-1 agonists Synergy StackComprehensive weight management — appetite suppression + cellular metabolic optimization
GLP-1 agonists reduce caloric intake via appetite suppression and gastric slowing. 5-Amino-1MQ works at the cellular level to optimize how remaining energy is processed, favoring fat oxidation. The combination addresses both intake and metabolism.
5-Amino-1MQ 50–100 mg daily oral, alongside established semaglutide protocol.
Metformin
Metabolic Optimization StackMetabolic health and insulin sensitivity enhancement
Both compounds improve insulin sensitivity through different mechanisms — metformin via AMPK activation and mitochondrial complex I inhibition; 5-Amino-1MQ via SIRT1 activation from elevated NAD+. Potential additive effect on glucose regulation.
5-Amino-1MQ 50–100 mg daily; metformin per physician guidance. Not to be combined without medical supervision.